多発性硬化症治療の世界市場レポート2025年

多発性硬化症治療の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.8%で315億5,000万米ドルに成長します。このような成長が予想される背景には、新規モノクローナル抗体の承認の増加、MSの個別化治療に対する需要の高まり、神経変性疾患の管理への重点化、MS治療における遠隔医療の普及、低侵襲治療へのシフトなどがあります。予測期間中に予想される注目すべき動向には、遠隔モニタリング技術の進歩、再髄鞘化療法の開発、腸脳軸アプローチの探求、デジタルバイオマーカーの統合、デジタル治療薬の革新などがあります。

神経疾患の有病率の増加が多発性硬化症治療市場の成長を牽引すると予測されます。神経疾患は、脳、脊髄、神経に影響を及ぼす疾患で、その結果、運動、コミュニケーション、行動、身体機能に課題が生じる。このような神経疾患の増加は、平均寿命の延長によりアルツハイマー病のような加齢性疾患のリスクが高まるため、主に高齢化が原因となっています。多発性硬化症治療は、免疫系を調節して炎症を抑え、神経損傷を最小限に抑え、症状を緩和し、最終的に患者の生活の質を高めることによって、このような神経学的問題を管理する上で重要な役割を果たしています。例えば、2023年10月、英国を拠点とし各国の神経学会を代表する組織である世界神経学連合は、現在世界人口の40％以上が何らかの神経疾患に罹患しており、この数字は2050年までにほぼ倍増すると予想されると報告しました。その結果、神経疾患の有病率の上昇が多発性硬化症治療市場の拡大に大きく寄与しています。

多発性硬化症治療領域で事業を展開する企業は、治療結果や有効性を向上させるため、モノクローナル抗体医薬などの先端治療薬の開発にますます力を注いでいます。モノクローナル抗体は、特定の抗原を標的とするように設計された研究室内で設計された分子であり、多発性硬化症の文脈では、炎症を最小限に抑え、免疫細胞の攻撃から神経線維を保護し、それによって病気の進行を遅らせることで機能します。例えば、2024年2月、インドの製薬会社ロシュ・ファーマ・インディアは、多発性硬化症の治療薬としてオクレブス（オクレリズマブ）を発売しました。この薬はCD20陽性B細胞を特異的に標的とし、炎症と神経損傷を抑えます。再発型および一次進行型MSの両方に承認された初めての治療薬であり、再発率を有意に低下させ、障害の進行を遅らせることが知られています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の多発性硬化症治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の多発性硬化症治療市場：成長率分析
• 世界の多発性硬化症治療市場の実績：規模と成長, 2019-2024
• 世界の多発性硬化症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の多発性硬化症治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の多発性硬化症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬
• コルチコステロイド
• 対症療法
• モノクローナル抗体
• 経口療法
• 世界の多発性硬化症治療市場疾患の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床的に孤立した症候群
• 再発寛解型多発性硬化症
• 原発性進行性多発性硬化症
• 二次進行性多発性硬化症
• 世界の多発性硬化症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 静脈内
• 世界の多発性硬化症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の多発性硬化症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の多発性硬化症治療市場免疫調節剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロンベータ1A
• インターフェロンベータ1B
• グラチラマー酢酸塩
• 世界の多発性硬化症治療市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メチルプレドニゾロン
• プレドニゾン
• デキサメタゾン
• 世界の多発性硬化症治療市場対症療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 筋弛緩剤
• 抗うつ薬
• 抗けいれん薬
• 膀胱機能障害治療薬
• 世界の多発性硬化症治療市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナタリズマブ
• オクレリズマブ
• アレムツズマブ
• オファツムマブ
• 世界の多発性硬化症治療市場、経口療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィンゴリモド
• ジメチルフマル酸
• テリフルノミド
• クラドリビン
• シポニモド

第7章 地域別・国別分析

• 世界の多発性硬化症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多発性硬化症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性硬化症治療市場：競合情勢
• 多発性硬化症治療市場：企業プロファイル
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Biogen Inc.
• UCB S.A.
• Mallinckrodt Pharmaceuticals
• Acorda Therapeutics Inc.
• Adamas Pharmaceuticals Inc.
• Mapi Pharma Ltd.
• TG Therapeutics Inc.
• Atara Biotherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多発性硬化症治療市場2029：新たな機会を提供する国
• 多発性硬化症治療市場2029：新たな機会を提供するセグメント
• 多発性硬化症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multiple sclerosis (MS) treatment encompasses medical strategies and therapies designed to manage symptoms, slow disease progression, and enhance the quality of life for individuals with MS, a chronic autoimmune condition that impacts the central nervous system. These treatments include disease-modifying therapies (DMTs) and symptomatic interventions that address issues such as fatigue, muscle spasms, and mobility difficulties. The primary goal of MS treatment is to support neurological function and improve patients' overall well-being.

Key types of MS treatments include immunomodulators, corticosteroids, symptomatic therapies, monoclonal antibodies, and oral medications. Immunomodulators, such as interferon beta and glatiramer acetate, work by modifying immune system activity to reduce inflammation and prevent relapses. MS-related conditions include clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, and secondary progressive MS. Treatment delivery methods include oral, injectable, and intravenous routes, and these are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The treatments cater to various end users, including hospitals, specialty clinics, homecare settings, and others.

The multiple sclerosis treatment market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis treatment market statistics, including the multiple sclerosis treatment industry's global market size, regional shares, competitors with the multiple sclerosis treatment market share, detailed multiple sclerosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis treatment industry. This multiple sclerosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple sclerosis treatment market size has grown strongly in recent years. It will grow from $24.86 billion in 2024 to $26.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. This growth during the historical period was driven by heightened awareness of early MS symptoms, expanded access to disease-modifying therapies, rising incidence of autoimmune disorders, improved neurological healthcare infrastructure, and growing use of immunomodulatory drugs.

The multiple sclerosis treatment market size is expected to see steady growth in the next few years. It will grow to $31.55 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. This anticipated growth is attributed to increasing approvals of novel monoclonal antibodies, heightened demand for personalized MS treatments, enhanced focus on managing neurodegenerative diseases, wider use of telemedicine in MS care, and a shift toward minimally invasive treatment approaches. Notable trends expected in the forecast period include advancements in remote monitoring technologies, the development of remyelination therapies, exploration of gut-brain axis approaches, the integration of digital biomarkers, and innovation in digital therapeutics.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the multiple sclerosis treatment market. Neurological disorders are conditions that impact the brain, spinal cord, and nerves, resulting in challenges with movement, communication, behavior, or bodily functions. This rise in neurological conditions is primarily attributed to an aging population, as longer life expectancies heighten the risk of age-related disorders like Alzheimer's disease. Multiple sclerosis treatments play a crucial role in managing such neurological issues by modulating the immune system to reduce inflammation, minimize nerve damage, and alleviate symptoms, ultimately enhancing patients' quality of life. For example, in October 2023, the World Federation of Neurology, a UK-based organization representing national neurological societies, reported that over 40% of the global population is currently affected by some form of neurological condition, with this figure expected to nearly double by 2050. As a result, the rising prevalence of neurological disorders is significantly contributing to the expansion of the multiple sclerosis treatment market.

Companies operating in the multiple sclerosis treatment space are increasingly focusing on the development of advanced therapies, such as monoclonal antibody drugs, to improve treatment outcomes and efficacy. Monoclonal antibodies are lab-engineered molecules designed to target specific antigens, and in the context of multiple sclerosis, they work by minimizing inflammation and protecting nerve fibers from immune cell attacks, thereby slowing disease progression. For instance, in February 2024, Roche Pharma India, an Indian pharmaceutical company, launched Ocrevus (Ocrelizumab) to treat multiple sclerosis. This drug specifically targets CD20-positive B cells to reduce inflammation and nerve damage. It is the first therapy approved for both relapsing and primary progressive forms of MS and is known to significantly lower relapse rates and slow disability progression with the added benefit of biannual infusions.

In March 2024, Juvise Pharmaceuticals, a pharmaceutical company based in France, acquired a multiple sclerosis drug from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition aims to broaden Juvise Pharmaceuticals' neurology portfolio beyond the US and Canadian markets, while also involving financial support from Bpifrance and Pemberton to back its future growth strategies. Actelion Pharmaceuticals Ltd., based in Switzerland, is a pharmaceutical company actively engaged in multiple sclerosis treatment development.

Major players in the multiple sclerosis treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Mallinckrodt Pharmaceuticals, Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Mapi Pharma Ltd., TG Therapeutics Inc., Atara Biotherapeutics Inc.

North America was the largest region in the multiple sclerosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in multiple sclerosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multiple sclerosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple sclerosis treatment market consists of sales of products including disease-modifying therapies, synthetic polypeptides, cannabinoid-based therapies, interferon beta products, and plasma exchange. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Sclerosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple sclerosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple sclerosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple sclerosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Immunomodulators; Corticosteroids; Symptomatic Treatments; Monoclonal Antibodies; Oral Therapies
• 2) By DiseaseType: Clinically Isolated Syndrome; Relapse-Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
• 3) By Route Of Administration: Oral; Injectable; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments

• 1) By Immunomodulators: Interferon Beta-1A; Interferon Beta-1B; Glatiramer Acetate
• 2) By Corticosteroids: Methylprednisolone; Prednisone; Dexamethasone
• 3) By Symptomatic Treatments: Muscle Relaxants; Antidepressants; Anticonvulsants; Bladder Dysfunction Drugs
• 4) By Monoclonal Antibodies: Natalizumab; Ocrelizumab; Alemtuzumab; Ofatumumab
• 5) By Oral Therapies: Fingolimod; Dimethyl Fumarate; Teriflunomide; Cladribine; Siponimod
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Merck And Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Sclerosis Treatment Market Characteristics

3. Multiple Sclerosis Treatment Market Trends And Strategies

4. Multiple Sclerosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Multiple Sclerosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multiple Sclerosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multiple Sclerosis Treatment Market Growth Rate Analysis
• 5.4. Global Multiple Sclerosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multiple Sclerosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multiple Sclerosis Treatment Total Addressable Market (TAM)

6. Multiple Sclerosis Treatment Market Segmentation

• 6.1. Global Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulators
• Corticosteroids
• Symptomatic Treatments
• Monoclonal Antibodies
• Oral Therapies
• 6.2. Global Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinically Isolated Syndrome
• Relapse-Remitting Multiple Sclerosis
• Primary Progressive Multiple Sclerosis
• Secondary Progressive Multiple Sclerosis
• 6.3. Global Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intravenous
• 6.4. Global Multiple Sclerosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Multiple Sclerosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Beta-1A
• Interferon Beta-1B
• Glatiramer Acetate
• 6.7. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methylprednisolone
• Prednisone
• Dexamethasone
• 6.8. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Symptomatic Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Muscle Relaxants
• Antidepressants
• Anticonvulsants
• Bladder Dysfunction Drugs
• 6.9. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natalizumab
• Ocrelizumab
• Alemtuzumab
• Ofatumumab
• 6.10. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Oral Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fingolimod
• Dimethyl Fumarate
• Teriflunomide
• Cladribine
• Siponimod

7. Multiple Sclerosis Treatment Market Regional And Country Analysis

• 7.1. Global Multiple Sclerosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multiple Sclerosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Sclerosis Treatment Market

• 8.1. Asia-Pacific Multiple Sclerosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Sclerosis Treatment Market

• 9.1. China Multiple Sclerosis Treatment Market Overview
• 9.2. China Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Sclerosis Treatment Market

• 10.1. India Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Sclerosis Treatment Market

• 11.1. Japan Multiple Sclerosis Treatment Market Overview
• 11.2. Japan Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Sclerosis Treatment Market

• 12.1. Australia Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Sclerosis Treatment Market

• 13.1. Indonesia Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Sclerosis Treatment Market

• 14.1. South Korea Multiple Sclerosis Treatment Market Overview
• 14.2. South Korea Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Sclerosis Treatment Market

• 15.1. Western Europe Multiple Sclerosis Treatment Market Overview
• 15.2. Western Europe Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Sclerosis Treatment Market

• 16.1. UK Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Sclerosis Treatment Market

• 17.1. Germany Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Sclerosis Treatment Market

• 18.1. France Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Sclerosis Treatment Market

• 19.1. Italy Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Sclerosis Treatment Market

• 20.1. Spain Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Sclerosis Treatment Market

• 21.1. Eastern Europe Multiple Sclerosis Treatment Market Overview
• 21.2. Eastern Europe Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Sclerosis Treatment Market

• 22.1. Russia Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Sclerosis Treatment Market

• 23.1. North America Multiple Sclerosis Treatment Market Overview
• 23.2. North America Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Sclerosis Treatment Market

• 24.1. USA Multiple Sclerosis Treatment Market Overview
• 24.2. USA Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Sclerosis Treatment Market

• 25.1. Canada Multiple Sclerosis Treatment Market Overview
• 25.2. Canada Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Sclerosis Treatment Market

• 26.1. South America Multiple Sclerosis Treatment Market Overview
• 26.2. South America Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Sclerosis Treatment Market

• 27.1. Brazil Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Sclerosis Treatment Market

• 28.1. Middle East Multiple Sclerosis Treatment Market Overview
• 28.2. Middle East Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Sclerosis Treatment Market

• 29.1. Africa Multiple Sclerosis Treatment Market Overview
• 29.2. Africa Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Sclerosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Multiple Sclerosis Treatment Market Competitive Landscape
• 30.2. Multiple Sclerosis Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Sclerosis Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc
• 31.5. Eli Lilly and Company
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Mylan N.V.
• 31.8. Biogen Inc.
• 31.9. UCB S.A.
• 31.10. Mallinckrodt Pharmaceuticals
• 31.11. Acorda Therapeutics Inc.
• 31.12. Adamas Pharmaceuticals Inc.
• 31.13. Mapi Pharma Ltd.
• 31.14. TG Therapeutics Inc.
• 31.15. Atara Biotherapeutics Inc.

32. Global Multiple Sclerosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Sclerosis Treatment Market

34. Recent Developments In The Multiple Sclerosis Treatment Market

35. Multiple Sclerosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Multiple Sclerosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multiple Sclerosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multiple Sclerosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer